drugset / Trial / NCT02943655

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

NCT02943655

Phase 3 Completed 240 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow, frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic disease.

Timeline

Start
2017-11-01
Primary completion
2020-10-10
Completion
2021-02-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mefenamic acid Small molecule 500 mg Oral
Comparator medroxyprogesterone acetate Other / unclassified 5 mg Oral
Comparator microcept Unknown Oral

Indications

No indication recorded.